Wells Fargo & Company Cuts Affimed (NASDAQ:AFMD) Price Target to $25.00

Affimed (NASDAQ:AFMD - Free Report) had its price target trimmed by Wells Fargo & Company from $30.00 to $25.00 in a research report sent to investors on Monday, Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company's stock.

AFMD has been the subject of a number of other research reports. StockNews.com assumed coverage on Affimed in a research report on Tuesday, January 2nd. They issued a sell rating for the company. HC Wainwright upped their price objective on shares of Affimed to $10.00 and gave the company a buy rating in a research note on Monday. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $45.00.

Affimed Trading Up 19.8 %

Shares of NASDAQ:AFMD traded up $1.05 during trading on Monday, reaching $6.35. The stock had a trading volume of 228,194 shares, compared to its average volume of 94,291. The stock has a market cap of $94.81 million, a P/E ratio of -0.76 and a beta of 2.05. The company has a quick ratio of 3.67, a current ratio of 3.70 and a debt-to-equity ratio of 0.10. Affimed has a fifty-two week low of $2.23 and a fifty-two week high of $11.10. The business has a fifty day moving average price of $5.45 and a 200-day moving average price of $4.90.

Institutional Investors Weigh In On Affimed

Several institutional investors and hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its stake in shares of Affimed by 30.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 3,202 shares in the last quarter. Vanguard Group Inc. grew its stake in Affimed by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 1,386,701 shares of the biopharmaceutical company's stock valued at $6,060,000 after purchasing an additional 5,499 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Affimed by 1.9% during the 1st quarter. Bank of New York Mellon Corp now owns 302,737 shares of the biopharmaceutical company's stock worth $1,323,000 after purchasing an additional 5,513 shares during the last quarter. Advisor Group Holdings Inc. boosted its stake in shares of Affimed by 258.3% during the 1st quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 6,464 shares during the last quarter. Finally, Virtu Financial LLC grew its position in shares of Affimed by 27.9% during the second quarter. Virtu Financial LLC now owns 29,836 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 6,509 shares in the last quarter. Hedge funds and other institutional investors own 30.82% of the company's stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.